Figure 1.
Figure 1. FBXL5 deficiency promotes liver carcinogenesis. (A) Gross appearance of the liver of DEN-injected Fbxl5F/F (control) and Alb-Cre/Fbxl5F/F male mouse littermates at 36 wk of age. Bar, 10 mm. (B) Tumor multiplicity and maximal tumor diameter for the liver of DEN-injected Fbxl5F/F (male, n = 24; female, n = 6), Alb-Cre/Fbxl5F/F (male, n = 22; female, n = 4), and Fbxl5−/−Irp2−/− (male, n = 13; female, n = 6) mice at 36 wk of age. Horizontal bars are means. *, P < 0.05; **, P < 0.01; ***, P < 0.005 (one-way ANOVA followed by Tukey’s test). (C) Hematoxylin-eosin staining of liver sections from DEN-injected Fbxl5F/F and Alb-Cre/Fbxl5F/F male mouse littermates at 36 wk of age. Arrowheads indicate a liver tumor. Bars, 200 µm.

FBXL5 deficiency promotes liver carcinogenesis. (A) Gross appearance of the liver of DEN-injected Fbxl5F/F (control) and Alb-Cre/Fbxl5F/F male mouse littermates at 36 wk of age. Bar, 10 mm. (B) Tumor multiplicity and maximal tumor diameter for the liver of DEN-injected Fbxl5F/F (male, n = 24; female, n = 6), Alb-Cre/Fbxl5F/F (male, n = 22; female, n = 4), and Fbxl5−/−Irp2−/− (male, n = 13; female, n = 6) mice at 36 wk of age. Horizontal bars are means. *, P < 0.05; **, P < 0.01; ***, P < 0.005 (one-way ANOVA followed by Tukey’s test). (C) Hematoxylin-eosin staining of liver sections from DEN-injected Fbxl5F/F and Alb-Cre/Fbxl5F/F male mouse littermates at 36 wk of age. Arrowheads indicate a liver tumor. Bars, 200 µm.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal